Mapping and characterization of iron compounds in Alzheimer's tissue.
Understanding the management of iron in the brain is of great importance in the study of neurodegeneration, where regional iron overload is frequently evident. A variety of approaches have been employed, from quantifying iron in various anatomical structures, to identifying genetic risk factors related to iron metabolism, and exploring chelation approaches to tackle iron overload in neurodegenerative disease. However, the ease with which iron can change valence state ensures that it is present in vivo in a wide variety of forms, both soluble and insoluble. Here, we review recent developments in approaches to locate and identify iron compounds in neurodegenerative tissue. In addition to complementary techniques that allow us to quantify and identify iron compounds using magnetometry, extraction, and electron microscopy, we are utilizing a powerful combined mapping/characterization approach with synchrotron X-rays. This has enabled the location and characterization of iron accumulations containing magnetite and ferritin in human Alzheimer's disease (AD) brain tissue sections in situ at micron-resolution. It is hoped that such approaches will contribute to our understanding of the role of unusual iron accumulations in disease pathogenesis, and optimise the potential to use brain iron as a clinical biomarker for early detection and diagnosis.
Collingwood
Joanna
J
Institute of Science and Technology in Medicine, Keele University, Staffordshire, ST4 7QB, UK.
Dobson
Jon
J
D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D001921:Brain / Q000378:metabolism* / Q000473:pathology*; D005293:Ferritins / Q000378:metabolism*; D052203:Ferrosoferric Oxide / Q000378:metabolism*; D006485:Hemosiderin / Q000378:metabolism*; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008854:Microscopy, Electron; D017356:Synchrotrons / Q000295:instrumentation
D005293:Ferritins; D006485:Hemosiderin; D007501:Iron; D052203:Ferrosoferric Oxide